Evidence map›Paper›PMID 39338408›Full record

ArticlePharmaceuticals (Basel, Switzerland)2024

Real-Time Fluorescence Monitoring System for Optimal Light Dosage in Cancer Photoimmunotherapy.

Hideki Tanaka, Yoshikatsu Koga, Mayumi Sugahara, Hirobumi Fuchigami, Akihiro Ishikawa, Toru Yamaguchi, Akiko Banba, Takeshi Shinozaki, Kazuto Matsuura, Ryuichi Hayashi and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Pharmaceuticals (Basel, Switzerland), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Hideki TanakaDepartment of Head and Neck Surgery, National Cancer Center Hospital East, Kashiwa 277-8577, Japan.ORCID 0000-0002-0936-0905
Yoshikatsu KogaDepartment of Strategic Programs, Exploratory Oncology Research & Clinical Trial Center, National Cancer Center, Kashiwa 277-8577, Japan.ORCID 0000-0002-8404-585X
Mayumi SugaharaDepartment of Gastroenterology and Endoscopy, National Cancer Center Hospital East, Kashiwa 277-8577, Japan.
Hirobumi FuchigamiDivision of Developmental Therapeutics, Exploratory Oncology Research & Clinical Trial Center, National Cancer Center, Kashiwa 277-8577, Japan.
Akihiro IshikawaShimadzu Corporation, Kyoto 604-8511, Japan.
Toru YamaguchiShimadzu Corporation, Kyoto 604-8511, Japan.
Akiko BanbaShimadzu Corporation, Kyoto 604-8511, Japan.
Takeshi ShinozakiDepartment of Head and Neck Surgery, National Cancer Center Hospital East, Kashiwa 277-8577, Japan.ORCID 0000-0001-6762-8490
Kazuto MatsuuraDepartment of Head and Neck Surgery, National Cancer Center Hospital East, Kashiwa 277-8577, Japan.
Ryuichi HayashiDepartment of Head and Neck Surgery, National Cancer Center Hospital East, Kashiwa 277-8577, Japan.
Shingo SakashitaDivision of Developmental Pathology, Exploratory Oncology Research & Clinical Trial Center, National Cancer Center, Kashiwa 277-8577, Japan.
Masahiro YasunagaDivision of Developmental Therapeutics, Exploratory Oncology Research & Clinical Trial Center, National Cancer Center, Kashiwa 277-8577, Japan.
Tomonori YanoDepartment of Gastroenterology and Endoscopy, National Cancer Center Hospital East, Kashiwa 277-8577, Japan.

Funding

Shimadzu (Japan) C2021-002
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

antibody–drug conjugateanticancer therapyfluorescence imagingIR700photoimmunotherapyreal-time imaging

Identifiers

PMID39338408
PMCPMC11435081

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.